UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 8,414	$ 7,638
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	310	302
Amortization	3,207	3,257
Provision for (recovery of) losses on accounts receivable	(26)	26
Amortization of Right of Use Assets	26	26
Deferred income taxes	(137)	(286)
Stock-based compensation expense	100	83
Tax benefit attributable to exercise of stock options	9	0
Changes in operating assets and liabilities
Accounts receivable and other receivables	2,044	102
Inventories	(1,245)	(930)
Prepaid expenses and other current assets	3	(47)
Accounts payable	114	64
Accrued expenses	(991)	(357)
Total adjustments	3,414	2,240
Net cash provided by operating activities	11,828	9,878
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(363)	(450)
Intangible assets	0	(9)
Net cash used in investing activities	(363)	(459)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	81	23
Common stock purchased and retired	0	(2,495)
Payment of dividends	(2,140)	(1,060)
Net cash used in financing activities	(2,059)	(3,532)
Effect of exchange rate changes on cash	161	(637)
Net increase in cash and cash equivalents	9,567	5,250
Cash at beginning of period	75,052	60,974
Cash at end of period	84,619	66,224
Cash paid during the period for income taxes	2,546	2,467
Cash paid during the period for interest	$ 0	$ 0